NASH-TAG 2021

March 11-13, 2021

To help you get as much value from NASH-TAG 2021 as possible, we have identified several presentations and articles we find most interesting. Our daily podcasts will summarize these and discuss what they suggest for the future of NASH/NAFLD therapies.

Advanced Notification

S3-E40.5 - From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

S3-E40.5 – From the Vault: Why Cirrhosis Matters In Clinical Trial Strategy

This episode discusses the unique role NASH cirrhosis studies can play in clinical trial design, particularly in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.

S3-E40.3 - Importance of Early Diagnosis in Lean NASH

S3-E40.3 – Importance of Early Diagnosis in Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on why early diagnosis is so important when dealing with Lean NASH.

S3-E40.2 - A Simple Diagnostic Algorithm for Lean NASH

S3-E40.2 – A Simple Diagnostic Algorithm for Lean NASH

Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the elegant one-page diagnostic algorithm they recommend for diagnosing Lean NASH in “normal” BMI patients with signs of liver disease.